PLGA from PolySciTech used in development of anti-inflammatory P7C3 delivery system for wound-healing

 

There are several steps along the inflammation pathway and this bodily response often delays or prevents the progression of wound-healing. Targeted prevention of inflammation can be leveraged to provide for treatment of a wide range of disease states. Researchers at University of South Florida and St. John Fisher University used PLGA (cat# AP040) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create P7C3 delivery nanoparticle and tested these for delivery of this potent, anti-inflammatory compound. This research holds promise to provide treatment for inflammatory diseases. Read more: Sutariya, Vijaykumar, Priyanka Bhatt, Aren Saini, Abraian Miller, Sachin L. Badole, Jared Tur, Mackenzie Gittinger, Joung Woul Kim, Ravikumar Manickam, and Srinivas M. Tipparaju. "Development and testing of nanoparticles delivery for P7C3 small molecule using injury models." Molecular and Cellular Biochemistry (2023): 1-17. https://link.springer.com/article/10.1007/s11010-023-04865-2

“The use of nanoparticles (NPs) has emerged as a potential tool for safe and effective drug delivery. In the present study, we developed small molecule P7C3-based NPs and tested its efficacy and toxicity along with the tissue specific aptamer-modified P7C3 NPs. The P7C3 NPs were prepared using poly (D, L-lactic-co-glycolic acid) carboxylic acid (PLGA-COOH) polymer, were conjugated with skeletal muscle-specific RNA aptamer (A01B P7C3 NPs) and characterized for its cytotoxicity, cellular uptake, and wound healing in vitro. The A01B P7C3 NPs demonstrated an encapsulation efficiency of 30.2 ± 2.6%, with the particle size 255.9 ± 4.3 nm, polydispersity index of 0.335 ± 0.05 and zeta potential of + 10.4 ± 1.8mV. The FTIR spectrum of P7C3 NPs displayed complete encapsulation of the drug in the NPs. The P7C3 NPs and A01B P7C3 NPs displayed sustained drug release in vitro for up to 6 days and qPCR analysis confirmed A01B aptamer binding to P7C3 NPs. The C2C12 cells viability assay displayed no cytotoxic effects of all 3 formulations at 48 and 72 h. In addition, the cellular uptake of A01B P7C3 NPs in C2C12 myoblasts demonstrated higher uptake. In vitro assay mimicking wound healing showed improved wound closure with P7C3 NPs. In addition, P7C3 NPs significantly decreased TNF-α induced NF-κB activity in the C2C12/NF-κB reporter cells after 24-hour treatment. The P7C3 NPs showed 3-4-fold higher efficacy compared to P7C3 solutions in both wound-closure and inflammation assays in C2C12 cells. Furthermore, the P7C3 NPs showed 3-4-fold higher efficacy in reducing the infarct size and protected mouse hearts from ex vivo ischemia-reperfusion injury. Overall, this study demonstrates the safe and effective delivery of P7C3 NPs. Keywords P7C3 · P7C3 nanoparticles · A01B RNA aptamer-conjugated P7C3 nanoparticles · Sustained release · Targeted delivery · Skeletal and cardiac muscle”

BPR (Biotech Pharma Research) Conference April 10, 2024 West Lafayette, Indiana http://bprconference.com/

Akina is hiring, see employment opportunities here: http://akinainc.com/employment.php